Fleischmann R, Shealy D: Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. In: Mol. Interv. 3. Jahrgang, Nr.6, September 2003, S.310–318, doi:10.1124/mi.3.6.310, PMID 14993463 (aspetjournals.org).
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, u. a.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. In: Arthritis Rheum. 52. Jahrgang, Nr.11, November 2005, S.3381–3390, doi:10.1002/art.21405, PMID 16258899 (rima.org [PDF]).
van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, u. a.: Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. In: Arthritis Rheum. 61. Jahrgang, Nr.1, Januar 2009, S.4–12, doi:10.1002/art.24367, PMID 19116965.
Fleischmann R, Shealy D: Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. In: Mol. Interv. 3. Jahrgang, Nr.6, September 2003, S.310–318, doi:10.1124/mi.3.6.310, PMID 14993463 (aspetjournals.org).
Augustsson J, Eksborg S, Ernestam S, Gullström E, van Vollenhoven R: Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. In: Ann Rheum Dis. 66. Jahrgang, Nr.11, November 2007, S.1462–1466, doi:10.1136/ard.2007.070771, PMID 17502359.
Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. In: Clin. Infect. Dis. 39. Jahrgang, Nr.3, August 2004, S.295–299, doi:10.1086/421494, PMID 15306993.
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, u. a.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. In: Arthritis Rheum. 52. Jahrgang, Nr.11, November 2005, S.3381–3390, doi:10.1002/art.21405, PMID 16258899 (rima.org [PDF]).
van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, u. a.: Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. In: Arthritis Rheum. 61. Jahrgang, Nr.1, Januar 2009, S.4–12, doi:10.1002/art.24367, PMID 19116965.
Fleischmann R, Shealy D: Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. In: Mol. Interv. 3. Jahrgang, Nr.6, September 2003, S.310–318, doi:10.1124/mi.3.6.310, PMID 14993463 (aspetjournals.org).
Augustsson J, Eksborg S, Ernestam S, Gullström E, van Vollenhoven R: Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. In: Ann Rheum Dis. 66. Jahrgang, Nr.11, November 2007, S.1462–1466, doi:10.1136/ard.2007.070771, PMID 17502359.
Gardam MA, Keystone EC, Menzies R, u. a.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. In: Lancet Infect Dis. 3. Jahrgang, Nr.3, März 2003, S.148–155, PMID 12614731.
Keane J, Gershon S, Wise RP, u. a.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. In: N. Engl. J. Med. 345. Jahrgang, Nr.15, Oktober 2001, S.1098–1104, PMID 11596589.
Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. In: Clin. Infect. Dis. 39. Jahrgang, Nr.3, August 2004, S.295–299, doi:10.1086/421494, PMID 15306993.
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, u. a.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. In: Arthritis Rheum. 52. Jahrgang, Nr.11, November 2005, S.3381–3390, doi:10.1002/art.21405, PMID 16258899 (rima.org [PDF]).